Drug Details
| General Information of the Drug (ID: DR4267) | ||||
|---|---|---|---|---|
| Name |
TRAIL/Apo2L
|
|||
| Disease | Lung cancer [ICD-11: 2C25] | Phase 3 | [1] | |
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Apigenin | Psilotum nudum | Click to Show/Hide the Molecular Data of This NP | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | SLC25A5 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
| LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2. | |||||
| Celastrol | Celastrus strigillosus | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | OVCAR-8 | CVCL_1629 | Ovarian serous adenocarcinoma | Homo sapiens | ||
| SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
| PLA-801D | CVCL_7110 | Lung giant cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Synergistic anticancer capabilities achieved by combining TRAIL/APO-2L and celastrol. | |||||
| Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A2780 | CVCL_0134 | Ovarian endometrioid adenocarcinoma | Homo sapiens | ||
| SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | |||
| ES-2 | CVCL_3509 | Ovarian clear cell adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combined curcumin and Apo2L/TRAIL treatment results in enhanced induction of apoptotic cell death. Curcumin and Apo2L/TRAIL together can activate both the extrinsic and intrinsic pathways of apoptosis. | |||||
| Gossypol | Gossypium herbaceum | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | ||
| NCI-H322 | CVCL_1556 | Lung adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Gossypol profoundly sensitizes thoracic cancer cells to the cytotoxic effect of Apo2L/TRAIL via activation of the mitochondria-dependent death signaling pathway. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Calcium channel alpha-1C (CACNA1C) | Molecule Info | [6] | |
| Calcium channel alpha-1I (CACNA1I) | Molecule Info | [6] | ||
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | Calcium signaling pathway | |||
| 3 | cGMP-PKG signaling pathway | |||
| 4 | cAMP signaling pathway | |||
| 5 | Cardiac muscle contraction | |||
| 6 | Adrenergic signaling in cardiomyocytes | |||
| 7 | Vascular smooth muscle contraction | |||
| 8 | Circadian entrainment | |||
| 9 | Long-term potentiation | |||
| 10 | Retrograde endocannabinoid signaling | |||
| 11 | Glutamatergic synapse | |||
| 12 | Cholinergic synapse | |||
| 13 | Serotonergic synapse | |||
| 14 | GABAergic synapse | |||
| 15 | Dopaminergic synapse | |||
| 16 | Insulin secretion | |||
| 17 | GnRH signaling pathway | |||
| 18 | Oxytocin signaling pathway | |||
| 19 | Type II diabetes mellitus | |||
| 20 | Alzheimer's disease | |||
| 21 | Amphetamine addiction | |||
| 22 | Hypertrophic cardiomyopathy (HCM) | |||
| 23 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | |||
| 24 | Dilated cardiomyopathy | |||
| 25 | MAPK signaling pathway | |||
| 26 | Calcium signaling pathway | |||
| 27 | Circadian entrainment | |||
| NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
| Panther Pathway | Alzheimer disease-amyloid secretase pathway | Click to Show/Hide | ||
| 2 | Nicotinic acetylcholine receptor signaling pathway | |||
| 3 | 5HT2 type receptor mediated signaling pathway | |||
| 4 | Beta1 adrenergic receptor signaling pathway | |||
| 5 | Beta2 adrenergic receptor signaling pathway | |||
| 6 | Oxytocin receptor mediated signaling pathway | |||
| 7 | Nicotine pharmacodynamics pathway | |||
| Pathwhiz Pathway | Muscle/Heart Contraction | Click to Show/Hide | ||
| Reactome | Adrenaline,noradrenaline inhibits insulin secretion | Click to Show/Hide | ||
| 2 | NCAM1 interactions | |||
| 3 | Regulation of insulin secretion | |||
| WikiPathways | Calcium Regulation in the Cardiac Cell | Click to Show/Hide | ||
| 2 | Arrhythmogenic Right Ventricular Cardiomyopathy | |||
| 3 | Alzheimers Disease | |||
| 4 | NCAM signaling for neurite out-growth | |||
| 5 | Integration of energy metabolism | |||
| 6 | Nicotine Activity on Chromaffin Cells | |||
